west china medical publishers
Author
  • Title
  • Author
  • Keyword
  • Abstract
Advance search
Advance search

Search

find Author "李晓密" 5 results
  • 心肌肽在心脏手术中应用的安全性观察

    摘要: 目的 探讨注射用心肌肽在体外循环心脏手术中使用的安全性。 方法 选择2008年4月至10月在我院心脏外科择期行心脏手术患者100例,并分为两组,实验组:50例,男27例,女23例;年龄46.50±17.80岁;患者在麻醉后静脉滴注心肌肽1 mg/kg,30 min完成;在第1次的灌注液中一次性加入心肌肽2 mg/kg;于术后第1 d,2 d和3 d静脉滴注心肌肽3 mg/kg。对照组: 50例,男24例,女26例;年龄50.10±20.40岁;患者给予相同剂量的5%葡萄糖溶液。 术后5~7 d检测血、尿常规及生化检查,行心电图和彩色超声心动图等安全性指标检测。 结果 术后实验组血、尿常规及生化指标包括肝功能(门冬氨酸氨基转移酶29.10±18.19 U/L vs. 37.27±21.81 U/L)、肾功能(血清肌酐65.84±22.69 μmol/L vs. 68.50±17.71 μmol/L),血糖、血清电解质、心率、ST段、左心室舒张期末内径(48.00±7.59 mm vs. 50.23±5.76 mm)、左心室射血分数(69.00%±7.00% vs. 67.00%±9.00%)与对照组比较差异均无统计学意义(Pgt;0.05)。 结论 注射用心肌肽在心脏手术围手术期对人体重要器官无明显影响,使用是安全的。

    Release date:2016-08-30 06:02 Export PDF Favorites Scan
  • Influence of Hydroxyethyl Starch on Blood Coagulation of Patients after off-pump Coronary Artery Bypass Grafting by Thromboelastography

    ObjectiveTo investigate the influence of 6% hydroxyethyl starch (HES, 130/0.4)on blood coagulation of patients after off-pump coronary artery bypass grafting (opCAB)by thromboelastography (TEG). MethodsOne hundred patients undergoing elective opCAB in Department of Cardiovascular Surgery, General Hospital of Shenyang Military Area Command between May and July 2013 were enrolled in this study. All the patients were randomly divided into 2 groups using random number table method with 50 patients in each group. In the experimental group (G1 group), there were 27 males and 23 females with their age of 64.9±4.4 years, who received intravenous 6% HES (130/0.4)20 ml/kg in 4 hours postoperatively. In the control group (G2 group), there were 31 males and 19 females with their age of 63.1±5.8 years, who received intravenous lactated ringers 20 ml/kg in 4 hours postoperatively. After postoperative ICU admission, full blood count, coagulation tests and TEG were examined. Chest and mediastinal drainage was recorded at 6 hours and 24 hours postoperatively. ResultsThere was no statistical difference in chest and mediastinal drainage 24 hours postoperatively between the 2 groups (591.7±171.7 ml vs. 542.4±174.0 ml, P > 0.05). None of the patients received reexploration for bleeding. There was no statistical difference in hemoglobin, hematocrit, platelet count or traditional coagulation index between the 2 groups (P > 0.05). TEG showed no significant change in coagulation time after intravenous fluid infusion in either group. Reaction time was slightly extended in both groups, but there was no statistical difference in reaction time between the 2 groups (P > 0.05). Maximum amplitude (MA)of G1 group was significantly decreased after intravenous fluid infusion (55.9±10.0 mm vs. 62.8±7.9 mm, P < 0.05), but still within the normal range. There was no significant change in MA after intravenous fluid infusion in G2 group. ConclusionIntravenous infusion of 6% HES (130/0.4)20 ml/kg can reduce platelet function and clot strength, but does not significantly increase postoperative chest or mediastinal drainage, or the incidence of postoperative reexploration for bleeding. It's safe to administer 6% HES (130/0.4)for patients after OPCAB.

    Release date: Export PDF Favorites Scan
  • APACHE Ⅱ for Severity Evaluation and Prognosis Prediction of Patients Undergoing Cardiac Surgery

    ObjectiveTo investigate acute physiologic and chronic health evaluation Ⅱ(APACHE Ⅱ) score system for severity evaluation and prognosis prediction of patients undergoing cardiac surgery. MethodsA total of 3 566 patients who were admitted in ICU after cardiac surgery in the Department of Cardiovascular Surgery of General Hospital of Shenyang Military between December 1, 2011 and August 31, 2013 were enrolled in this study. There were 1 873 males and 1 693 females with their average age of 45.8±23.7 years (range, 10 days to 82 years). All the patients were evaluated with APACHE Ⅱ and expected mortality was calculated. Receiver operating characteristic(ROC) curve was drawn to compare expected and actual mortality and evaluate predictive value of APACHE Ⅱ. ResultsA total of 3 373 patients survived the operation, and 193 patients died postoperatively with the mortality of 5.41%. The area under the ROC curve was 0.917 (P=0.000) with 95% confidence interval of[0.885,0.949]. The cut-off point of APACHE Ⅱ was 15.50, with a sensitivity of 80.3%,a specificity of 95.6%,an accuracy rate of 79.5%,a positive predictive value of 86.9%,and a negative predictive value of 93.1%. Expected and actual mortality increased with increasing APACHE Ⅱ,which were both positively correlated. ConclusionAPACHE Ⅱ score system can be used to evaluate severity and predict prognosis of patients undergoing cardiac surgery, which provides reference for rational utilization of ICU resource.

    Release date: Export PDF Favorites Scan
  • Bentall手术治疗马方综合征的疗效分析

    目的 评价Bentall手术治疗马方综合征(Marfan syndrome)的近、远期疗效。 方法 回顾性分析沈阳军区总医院1998年3月至2011年2月连续收治的65例马方综合征患者的临床资料,其中男41例,女24例;年龄8~62(42.1±13.3)岁。合并主动脉夹层动脉瘤De BakeyⅠ型14例,Ⅱ型2例;重度主动脉瓣关闭不全42例,中度二尖瓣关闭不全7例,中度三尖瓣关闭不全4例。行经典法Bentall手术29例,纽扣法Bentall手术36例;同期行其它复杂手术18例。术后随访2~163个月, 分析Bentall手术治疗马方综合征近、远期疗效,同时比较行经典法与纽扣法Bentall手术患者的生存率。 结果 手术时间215~675 (359.0±104.0) min,体外循环时间103~318 (157.0±41.0) min,主动脉阻断时间60~159 (94.0±25.0) min,深低温停循环时间13~35 (23.0±7.0) min。术后住重症监护室时间1~21 (5.4±3.5) d,机械通气辅助时间1~11 (2.3±2.2) d,住院时间8~59 (28.1±10.6) d。住院死亡4例(6.1%),术后早期并发症25例(38.5%)。随访期间死亡12例(19.7%),远期并发症11例(18.0%)。所有痊愈出院患者1年、3年、5年和10年生存率分别为96.5%±2.5%、86.1%±4.9%、77.5%±6.5%和69.7%±7.9%,生存(10.6±0.7)年,95% CI (9.1,12.0)。行纽扣法Bentall手术患者生存率高于经典法Bentall手术,且差异有统计学意义(P=0.034)。 结论 Bentall手术治疗马方综合征安全、有效,近期及远期结果满意,行纽扣法Bentall手术患者生存率更高。

    Release date:2016-08-30 05:28 Export PDF Favorites Scan
  • Short-term effect of minimally invasive thoracoscopic cardiac surgery in 453 patients: A retrospective study in a single center

    ObjectiveTo analyze the short-term outcomes of cardiac surgery via minimally invasive approach under thoracoscope in a single-center. Methods The clinical data of patients who underwent cardiac surgery via minimally invasive approach under thoracoscope between July 2017 and February 2022 were retrospectively analyzed. Results A total of 453 patients were enrolled, including 150 males and 303 females at an average age of 42.2±14.6 years. The main disease types included atrial septal defect in 314 patients, partial atrioventricular septal defect in 26 patients, and cardiac tumor in 105 patients. There was no death during the perioperative period. The mean operative time was 3.9±0.8 h, cardiopulmonary bypass time was 101.2±34.0 min, aortic occlusion time was 42.1±25.1 min, ventilator assistance time was 11.6±9.4 h, ICU stay time was 22.6±13.9 h and postoperative hospital stay was 6.0±1.7 d. Intraoperative and postoperative complications occurred in 18 (4.0%) patients, including 2 patients with conversion to sternotomy, 3 with incision expand, 3 with reoperation for bleeding, 1 with of redo operation, 4 with incision infection, 2 with respiratory insufficiency, 2 with cerebrovascular accident, and 1 with ventricular fibrillation. The follow-up time was 22.6±15.4 months, during which 1 patient died, 4 patients had moderate mitral regurgitation, 1 patient had mild-moderate mitral regurgitation, and 1 patient had mild-moderate tricuspid regurgitation. Conclusion Minimally invasive cardiac surgery under thoracoscope is safe with small invasions and few complications, and has satisfactory short-term outcomes.

    Release date: Export PDF Favorites Scan
1 pages Previous 1 Next

Format

Content